# TAR-210

Source: https://onco.cc/drugs/tar-210/  
OnCo record `tar-210` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TAR-210 is an experimental small molecule (intravesical drug-releasing system) from Janssen Research & Development in phase 3 trials for bladder & urothelial cancer, aimed at FGFR2.

## Summary

TAR-210 (JNJ-42756493) is a small molecule (intravesical drug-releasing system) developed by Janssen Research & Development. Its target is FGFR2 (the sponsor names FGFR (fibroblast growth factor receptor)). The sponsor states: An intravesical system that provides approximately two years of continuous local bladder delivery of erdafitinib, an FGFR inhibitor, for patients with high-risk non-muscle-invasive bladder cancer harbouring susceptible FGFR alterations. ClinicalTrials.gov describes the intervention as: TAR-210 will be administered intravesically. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06919965 (A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer), in bladder & urothelial cancer. The largest, NCT06919965, plans to enrol 220 participants with primary completion expected 2028-04-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: JNJ-42756493
- Modality: small molecule (intravesical drug-releasing system)
- Mechanism: An intravesical system that provides approximately two years of continuous local bladder delivery of erdafitinib, an FGFR inhibitor, for patients with high-risk non-muscle-invasive bladder cancer harbouring susceptible FGFR alterations.

## Sources

- ClinicalTrials.gov: trials of TAR-210: https://clinicaltrials.gov/search?intr=JNJ-42756493

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- targets: [FGFR2](https://onco.cc/targets/fgfr2/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)
- trials: [A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer](https://onco.cc/trials/nct06919965/), [A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer](https://onco.cc/trials/nct06319820/)

---
JSON: https://onco.cc/api/v1/entities/tar-210.json